Introducing the team
Ester Sklarsky
M.Sc., Principal
Thomas Tan
D. Phil., Principal
Casper Breum
M.Sc. MBA, Managing Partner
Johan Kördel
Ph.D., Managing Partner
Bibhash Mukhopadhyay
Ph.D., Managing Partner
Philip Brainin
MD, Ph.D, MBA, Associate
Fredrik Lehmann
ph.D, MBA, Entrepreneur-in-Residence
Anne Marie Simon
Office Manager
Sound Bioventures joins £19M ($24.5M) financing in UK oncolytic virus company Theolytics
Stockholm, Sweden and Washington D.C., USA – 17 April 2024 – Sound Bioventures, a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and the USA developing specialty therapeutics, today announced a new investment in Theolytics, a UK biotechnology company developing next-generation oncolytic vi …
Beyond fundraising: how do venture capitals build early-stage biotechs?
It’s no secret that venture capital is what drives early-stage drug development in the biotech industry. But beyond being a simple source of cash to spend on research, some VCs play a significant role in building the company with its founders. To better understand the dynamic between biotech startups and VCs, we talked to Johan […]
ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)
-ATX-01 is the industry’s first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX’s pipeline to enter the clinic – -First patient expected to be enrolled in Q2 2024- Valencia, Spain, February 28th, 2024 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the m …
Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158.
Safety and Efficacy Results Are Expected in Second Half of 2024 Evaluating AX-158, a First in Class Nck Blocker, Shifting the Paradigm of Autoimmune Disease Treatment. AX-158 Has Broad Potential to Treat Many Autoimmune Diseases without Causing Immunosuppression. Autoimmune Diseases Remain a Significant Unmet Medical Need, affecting Millions …